Ferry D R, Glossmann H
Naunyn Schmiedebergs Arch Pharmacol. 1984 Feb;325(2):186-9. doi: 10.1007/BF00506200.
The compound 1,4-dihydro-2,6-dimethyl-4-(2-trifluoromethylphenyl)-3, 5-pyridinecarboxylic acid 2-(amino-ethyl)ethylester was reacted with N-succinimidyl 3-(4-hydroxy, 5-125I-iodophenyl)propionate (2,200 Ci/mmol. The purified, 125I-labelled product of this reaction is termed 125I-iodipine and has a specific activity of approximately 2,200 Ci/mmol on the date of preparation. 125I-Iodipine binds reversibly in a saturable manner and with high affinity to skeletal muscle and brain membranes with KD values at 25 degrees C of 400 and 60 pmol/l, respectively. The binding of 125I-iodipine is stereoselectively inhibited by chiral 1,4-dihydropyridine calcium channel blockers. 125I-Iodipine labelled sites also recognize the recently described 1,4-dihydropyridine calcium channel activators and discriminate the chemically unrelated compounds (-)- and (+)verapamil, (-)- and (+)methoxyverapamil and d- and l-cis diltiazem. It is concluded that 125I-iodipine labels the putative calcium channel.
将化合物1,4 - 二氢 - 2,6 - 二甲基 - 4 - (2 - 三氟甲基苯基)-3,5 - 吡啶二甲酸2 - (氨基乙基)乙酯与N - 琥珀酰亚胺基3 - (4 - 羟基,5 - ¹²⁵I - 碘苯基)丙酸酯(2,200 Ci/mmol)反应。该反应纯化后的¹²⁵I标记产物称为¹²⁵I - 碘尼地平,制备当天其比活度约为2,200 Ci/mmol。¹²⁵I - 碘尼地平以可饱和的方式可逆结合,对骨骼肌和脑膜具有高亲和力,在25℃时的KD值分别为400和60 pmol/L。¹²⁵I - 碘尼地平的结合受到手性1,4 - 二氢吡啶钙通道阻滞剂的立体选择性抑制。¹²⁵I - 碘尼地平标记位点也识别最近描述的1,4 - 二氢吡啶钙通道激活剂,并区分化学上不相关的化合物(-) - 和(+) - 维拉帕米、(-) - 和(+) - 甲氧维拉帕米以及d - 和l - 顺式地尔硫䓬。得出结论:¹²⁵I - 碘尼地平标记了假定的钙通道。